期刊
ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS
卷 71, 期 1, 页码 -出版社
SPRINGER BASEL AG
DOI: 10.1007/s00005-023-00684-x
关键词
CAR-T; Colorectal cancer; Breast cancer; Solid tumor; Immunotherapy; Novel CAR-T targets; Challenges
类别
In recent years, the incidence of colorectal cancer (CRC) and breast cancer (BC) has increased worldwide. Immunosuppressive microenvironment, shortage of tumor-specific antigens, and post-treatment side effects are the major challenges in CAR-T therapy for CRC and BC. Clinical trials related to CAR-T immunotherapy against CRC or BC are underway, and this review provides valuable information for researchers and clinicians to overcome the challenges and explore novel CAR-T targets.
In recent years, the incidence of colorectal cancer (CRC) and breast cancer (BC) has increased worldwide and caused a higher mortality rate due to the lack of selective anti-tumor therapies. Current chemotherapies and surgical interventions are significantly preferred modalities to treat CRC or BC in advanced stages but the prognosis for patients with advanced CRC and BC remains dismal. The immunotherapy technique of chimeric antigen receptor (CAR)-T cells has resulted in significant clinical outcomes when treating hematologic malignancies. The novel CAR-T therapy target antigens include GUCY2C, CLEC14A, CD26, TEM8/ANTXR1, PDPN, PTK7, PODXL, CD44, CD19, CD20, CD22, BCMA, GD2, Mesothelin, TAG-72, CEA, EGFR, B7H3, HER2, IL13Ra2, MUC1, EpCAM, PSMA, PSCA, NKG2D. The significant aim of this review is to explore the recently updated information pertinent to several novel targets of CAR-T for CRC, and BC. We vividly described the challenges of CAR-T therapies when treating CRC or BC. The immunosuppressive microenvironment of solid tumors, the shortage of tumor-specific antigens, and post-treatment side effects are the major hindrances to promoting the development of CAR-T cells. Several clinical trials related to CAR-T immunotherapy against CRC or BC have already been in progress. This review benefits academicians, clinicians, and clinical oncologists to explore more about the novel CAR-T targets and overcome the challenges during this therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据